Aim: To delineate clinical correlates of COVID-19 infection severity in hospitalized patients with malignancy. Methods: The authors conducted a retrospective review of all hospitalized patients with a hematologic and/or solid tumor malignancy presenting to the authors’ institution between 1 March 2020 and 5 January 2021, with a laboratory confirmed diagnosis of COVID-19. Univariate and multivariate logistic regression analyses were used to determine associations between specific severity outcomes and clinical characteristics. Results: Among 2771 hospitalized patients with COVID-19, 246 (8.88%) met inclusion criteria. Patients who were actively receiving treatment had an increased rate of death following admission (odds ratio [OR]: 2.7). After adjusting for significant covariates, the odds ratio increased to 4.4. Patients with cancer involvement of the lungs had a trend toward increased odds of death after adjusting for covariates (OR: 2.3). Conclusions: Among COVID-19 positive hospitalized cancer patients, systemic anti-cancer therapy was associated with significantly increased odds of mortality. Plain language summary Though cancer is a biologically heterogenous disease with a wide spectrum of clinical features and behavior, accumulating evidence suggests that cancer patients are at greater susceptibility to COVID-19 infection and more likely to experience morbidity and mortality from COVID-19 infection than non-cancer patients. In this study, the authors reviewed the clinical characteristics of patients with a diagnosis of cancer hospitalized with COVID-19 to assess potential correlates of COVID-19 severity in this population. Notably, analysis of the hospital data revealed a statistically significant increased incidence of mortality in cancer patients who were receiving systemic anti-cancer treatment, including chemotherapy, immunotherapy or targeted therapy, than in those not on therapy. Likewise, there was a trend toward increased mortality in those with either primary or metastatic tumor involvement of the lung compared with those without lung involvement.
【저자키워드】 COVID-19, SARS-CoV-2, Cancer, lung cancer, lung metastasis, Hematologic malignancy, systemic anti-cancer therapy, 【초록키워드】 Treatment, therapy, Hospitalized, Mortality, Clinical characteristics, Immunotherapy, susceptibility, severity, lung involvement, hospital, COVID-19 severity, lung, outcome, Laboratory, Chemotherapy, COVID-19 infection, Patient, Cancer patients, death, morbidity and mortality, incidence, covariates, targeted therapy, anti-cancer treatment, disease, Admission, patients, clinical feature, association, Evidence, retrospective, Analysis, Odds ratio, malignancy, cancer patient, multivariate logistic regression, inclusion criteria, solid tumor, increased mortality, covariate, hematologic, positive, heterogenous, significantly increased, greater, conducted, receiving, were used, determine, hospitalized patient, statistically significant, presenting, accumulating, diagnosis of cancer, diagnosis of COVID-19, metastatic tumor, with COVID-19, 【제목키워드】 hospitalized COVID-19 patient, Diego,